ALS Pathology Investigated by Researchers from UCF & Hesperos Utilizing a Human-on-a-Chip model.
This is a test post about the ALS paper published in August
This is a test post about the ALS paper published in August
UCF/HESPEROS RESEARCHERS UTILIZE HUMAN-ON-A-CHIP® APPROACH TO MODEL ALS PATHOLOGY Key Findings Data supports use of functional neuromuscular junction (NMJ) system to evaluate amyotrophic lateral sclerosis pathology First study to validate the use of Deanna protocol in a human system as a strategy for treating ALS Press Release ORLANDO, Fla. — The Hybrid Systems Lab at … Read more
— New publication in Advanced Science validates potential use in evaluating certain immune responses in drug discovery and systemic diseases, including Coronavirus Disease 2019 (COVID-19)— — Hesperos’ immune system-on-a-chip features recirculating immune cells with the key organ mimics heart, skeletal muscle and liver ORLANDO, Fla. – June 2, 2020 — Hesperos Inc., pioneers of the … Read more
PRECLINICAL STAGES OF ALZHEIMER’S DISEASE AND MILD COGNITIVE IMPAIRMENT MODELED WITH HESPEROS HUMAN-ON-A-CHIP® SYSTEM — Peer-reviewed publication in Alzheimer’s & Dementia: Translational Research & Clinical Interventions validates potential of drug discovery platform and ability to study early stages of disease pathology — ORLANDO, Fla. – May 28, 2020 – Hesperos Inc., pioneers of the Human-on-a-Chip® … Read more
HUMAN-ON-A-CHIP FOR RARE DISEASES DISCUSSION In our latest publication, UCF & Hesperos researchers discuss how Human-on-a-chip systems can be used to address the unique challenges facing rare diseases. Researchers cite that rare diseases are “limited by the high cost of research and low target population.” Further Discussion of Human-on-a-chip® technology Researchers further discuss how “Human-on-a-chip … Read more
Dr. Francis Collins, director of The National Institutes of Health, recently featured Hesperos technology on his blog. In the post, Dr. Collins reviews a published study where Hesperos researchers investigated and treated several cancer lines with existing chemotherapeutics. The study both treated the cancer while reproducing known toxic effects of specific drugs and their more … Read more
Hesperos, Inc., (www.hesperosinc.com) announced today the University of Central Florida (UCF) received the first phase of a $3.8 million milestone-based National Institutes of Health (NIH) grant for research involving the company’s human-on-a-chip system. “We are grateful to have funding to support research in an area that represents such a large and growing need,” said Dr. … Read more
HUMAN-ON-A-CHIP PREDICTS IN VIVO RESULTS BASED ON IN VITRO MODEL FOR THE FIRST TIME Hesperos’ integrated heart-liver Human-on-a-Chip® shown to correctly determine cardiotoxic mechanisms preclinically and replicate results seen in in vivo studies (ORLANDO, Fla.) — Hesperos Inc., pioneers of the “human-on-a-chip” in vitro system has announced the use of its innovative multi-organ model to successfully measure the concentration and metabolism of two known … Read more
The interest in our human-on-a-chip model continues to grow. Last week we brought our systems to the National Center for Translational Science (NCATS) at the NIH in Washington, D.C. to perform a real-time demo using live cells. Hesperos, Inc. is the first company spun out from the Tissue Chip Program at NCATS. In attendance were … Read more